MBOAT4 and obesity due to melanocortin 4 receptor deficiency: The acylating enzyme, ghrelin-O-acyltransferase (GOAT), was recently proposed as a therapeutic target for obesity and type 2 diabetes [76] based on the assumption that it would reduce the production of active ghrelin and thereby decrease meal frequency.